LIFESCAPES Inc. is pleased to announce that it has been selected to participate in the “J-StarX Medical Data Utilization Program,” organized by the Japan External Trade Organization (JETRO) in cooperation with the Ministry of Economy, Trade and Industry (METI).

About the J-StarX Medical Data Utilization Program
To commercialize medical devices and digital health products in the United States, building robust clinical evidence that demonstrates product safety, efficacy, clinical utility, and cost-effectiveness is critical—not only for FDA regulatory clearance, but also for insurance reimbursement and adoption by healthcare institutions. Because domestic clinical data from Japan alone may not fully demonstrate utility within the U.S. patient population and healthcare environment, acquiring and validating necessary data in collaboration with local medical institutions and experts from an early stage of development is essential.
Supported by METI, JETRO’s “J-StarX Medical Data Utilization Program” assists Japanese medical startups in building the clinical evidence required to enter the U.S. market, while fostering network creation with medical institutions, Key Opinion Leaders (KOLs), regulatory and reimbursement experts, and investors.

Program Overview

• Program Name: J-StarX Medical Data Utilization Program
• Duration: July 2026 – March 2027
• Support Details: PoC / clinical data acquisition targeting FDA clearance and reimbursement, matching with clinical sites and KOLs, support for fundraising and business development, etc.
• Organizer: Japan External Trade Organization (JETRO)
• Partner: TheraNova LLC
• Details: https://www.jetro.go.jp/services/j-starx/medical_data_utilization.html

Through this selection, LIFESCAPES will accelerate the generation of clinical evidence in the United States and strive to deliver innovative treatment options to patients worldwide.